Shots:

• The P-III MAPLE study involves assessing of abicipar pegol (2mg- q8w) in 123 patients with Neovascular Macular Degeneration (nAMD) for 28 wks.
• P-III MAPLE study results: 8.9% incidence of intraocular inflammation (IOI)lower than P-III studies (CEDAR and SEQUOIA); severe IOI 1.6%; no reported cases of endophthalmitis or retinal vasculitis in this study
• Abicipar is an anti-VEGF therapy DARPin candidate administered q12w targeted for patients with nAMD. Allergan plans to file BLA to the US FDA in H1’19

Ref: Allergan | Image: Behance